Type 1 diabetes (T1D) is a chronic autoimmune condition that imposes a relentless daily burden on millions of people worldwide. For decades, research priorities were largely set by scientists and clinicians, often with limited direct input from the individuals who live with the disease. The Juvenile Diabetes Research Foundation (JDRF)—now simply JDRF International—has fundamentally changed that dynamic. By placing patients and their families at the heart of its mission, JDRF has redefined how diabetes research is conceived, funded, and evaluated. This patient-centered approach ensures that scientific breakthroughs translate into real-world improvements in quality of life, not just academic milestones.

JDRF was founded in 1970 by a group of parents of children with T1D who were frustrated by the slow pace of research and a lack of focus on practical solutions. From those early days, the organization has evolved into the largest global charitable funder of T1D research, having invested more than $2.5 billion in research and advocacy. What distinguishes JDRF from many other disease-focused foundations is its disciplined commitment to listening to the community it serves. Every research priority, from glucose monitoring to beta cell regeneration, is filtered through the question: “How will this make life better for someone with T1D today and tomorrow?”

The Shift from Lab-Centric to Patient-Centric Research

Historically, T1D research concentrated on understanding the underlying biology—the genetics, immunology, and metabolic pathways. While that foundational science remains essential, JDRF recognized early on that a purely mechanistic approach often produced advances that took years to reach patients, or that addressed problems patients did not consider most urgent. For example, an elegant gene therapy might have worked in mice but did little to help a teenager struggling with nocturnal hypoglycemia. The patient-centered model corrects this disconnect by ensuring that research portfolios reflect the lived experience of the disease.

This shift did not happen overnight. In the 1990s, JDRF began systematically incorporating patient and caregiver perspectives through structured engagement programs. Today, the organization uses a mix of quantitative surveys, qualitative focus groups, and ongoing advisory councils to identify pain points and desired outcomes. People with T1D and their families sit on scientific review committees, help shape funding calls, and even participate in data review sessions. The result is a research agenda that balances high-risk, high-reward science with pragmatic, near-term improvements.

How JDRF Gathers Patient Input

JDRF’s patient engagement is deeply embedded, not a token gesture. The organization runs a formal Patient Advocate Program that trains community members to understand research processes and contribute meaningfully. Advocates serve on study sections, attend grant review meetings, and provide input on research proposals. They do not vote on funding decisions—that remains the role of scientific experts—but their perspectives weigh heavily during discussions of feasibility, relevance, and potential impact.

Beyond the advocate program, JDRF fields regular community surveys. In 2022, for instance, the organization launched a global survey of more than 5,000 people with T1D and caregivers to rank research priorities. The results were clear: improving glucose control without increasing hypoglycemia risk, reducing the burden of constant monitoring, and finding ways to prevent or delay the onset of T1D emerged as top concerns. These findings directly influenced the funding of new artificial pancreas trials and expanded investment in immunotherapy prevention studies.

Additionally, JDRF hosts annual “Research Summits” that bring together scientists, clinicians, industry leaders, and patients for open dialogue. These summits are not one-way presentations; they include breakout sessions where patient stories inform workshop topics. The organization also runs online communities, such as the JDRF TypeOneNation platform, where individuals can share experiences and vote on research questions they want answered.

Patient-Informed Research Priorities in Detail

The patient-centered approach has reshaped the four main pillars of JDRF’s research strategy: glucose control, prevention, complications, and psychosocial support. While these categories are not new, the specific sub-priorities within them have been heavily influenced by community feedback.

Glucose Control: Beyond A1c

Patients consistently rank the unpredictability of glucose levels—and the fear of hypoglycemia—as their greatest daily challenge. JDRF has therefore prioritized technologies that reduce burden and increase time-in-range. The organization was instrumental in funding the early development of continuous glucose monitors (CGMs) and automated insulin delivery systems, commonly called artificial pancreas devices. More than 20 years ago, when CGM technology was still nascent, JDRF convened a consortium of engineers, clinicians, and patient advocates to define the ideal device attributes: accuracy, low calibration, comfort, and real-time data sharing with caregivers. That patient-driven specification led to the Dexcom G4 and subsequent models that transformed diabetes management.

Today, JDRF continues to fund next-generation systems that aim to be fully autonomous—requiring no user input for meal boluses or exercise adjustments. The community’s voice is critical here: patients have told researchers that they do not want a device that adds more alarms, more screen time, or more decision fatigue. So the current research emphasis is on “low-burden” automation that integrates with smart home devices and uses machine learning to anticipate glucose trends. JDRF also funds studies on closed-loop systems for preschool children, a population previously excluded from clinical trials due to safety concerns but now included because families demanded it.

Prevention and Delay of T1D

Preventing T1D has long been a scientific dream, but patients have helped reframe the goal from “cure” to “delay and mitigate severity.” A parent whose child tests positive for multiple autoantibodies may not want to wait for a perfect cure; they would welcome a therapy that postpones clinical diagnosis for years. The landmark Teplizumab trial, which showed that a short course of an anti-CD3 antibody could delay T1D onset by a median of two years, was funded partly by JDRF. Patient advocates pushed for the trial to include children as young as eight years old, arguing that preservation of beta cell function early in life had the greatest potential benefit.

Community input also drives JDRF’s investment in screening programs. The organization supports large-scale autoantibody screening initiatives, such as the Autoimmunity Screening for Kids (ASK) program, which tests children in general populations. Patients and parents were vocal about wanting to know their risk status, even when no preventive therapy exists, because it allows for earlier education and proactive monitoring. JDRF has responded by funding studies on how to communicate risk effectively without causing undue anxiety—a direct outcome of patient-centered research ethics.

Reducing Long-Term Complications

Research into the prevention and treatment of diabetic complications—retinopathy, nephropathy, neuropathy, and cardiovascular disease—has traditionally been separate from T1D-specific glucose management. But patients living with T1D experience these complications differently than those with type 2 diabetes. For example, the risk of hypoglycemia-associated autonomic failure is unique to T1D. JDRF’s complication research portfolio now includes patient-reported outcome measures that capture symptom burden, functional limitations, and quality of life, not just lab values.

One promising area is the use of sodium-glucose cotransporter-2 (SGLT2) inhibitors and GLP-1 receptor agonists in T1D, despite the risk of diabetic ketoacidosis. Clinical trials for these drugs were initially designed without adequate patient input on dose timing and ketone monitoring. JDRF funded a patient-led study that developed a home-based protocol for SGLT2 inhibitor use in T1D, which has since been adopted in several international trials. Similarly, research on diabetic kidney disease now includes patient advisory boards that help design endpoints such as “maintaining ability to exercise” rather than solely focusing on creatinine levels.

Psychosocial Support and Mental Health

Perhaps no area better illustrates the power of patient-centered research than the growing focus on mental health. For decades, the emotional toll of T1D was considered secondary to metabolic control. However, repeated surveys showed that depression, anxiety, and diabetes distress are as debilitating as any complication. JDRF responded by funding research on integrated care models that embed mental health professionals into diabetes clinics. The organization also supports digital therapeutics, such as cognitive behavioral therapy apps specifically designed for T1D-related distress.

Patient advocates also pushed for research into the social determinants of health in T1D: food insecurity, insurance coverage, and racial disparities. JDRF now funds studies examining how systemic inequities affect access to advanced diabetes technologies, and it has launched a health equity research initiative that includes community advisory boards from underrepresented populations. This expansion beyond the biomedical model is a direct result of listening to the diverse voices within the T1D community.

Impact on Research Translation and Speed

The patient-centered approach has not only shaped what is studied but how quickly discoveries move from lab to clinic. JDRF’s Industry Discovery Platform connects academic researchers with commercial partners, but only after patient reviewers have vetted the concept for real-world applicability. This early vetting reduces the likelihood that a promising animal study fails in humans because it solved a problem patients did not have.

Additionally, JDRF uses a “venture philanthropy” model, funding high-risk projects that might not attract traditional NIH grants. For example, the development of the first closed-loop insulin pump system for home use was accelerated by JDRF grants that required patient co-design. The result was the Medtronic 670G, the first hybrid closed-loop system approved by the FDA. Patients had insisted that the system should work with existing insulin pumps and keep the user interface simple—features that were incorporated early in development because JDRF required patient input at each milestone.

The organization also publishes clinical guidelines and advocacy positions that reflect patient priorities. For instance, JDRF successfully lobbied the Centers for Medicare & Medicaid Services to expand CGM coverage to older adults with diabetes, arguing that the patient experience of hypoglycemia is as dangerous in the elderly as in younger populations. This advocacy is grounded in data from patient-reported outcomes collected through JDRF-funded studies.

Challenges and Tensions in Patient-Centered Research

While the patient-centered model has many strengths, it is not without challenges. One tension is between what patients want and what science can deliver. For instance, a commonly voiced wish is for a “cure” that restores perfect insulin production without immunosuppression. That goal remains elusive, and researchers must sometimes pivot to partial solutions that patients may find disappointing. JDRF manages this by transparent communication about scientific hurdles and by involving patients in setting realistic timelines and intermediate milestones.

Another challenge is representing the diversity of the T1D community. Early patient engagement efforts tended to overrepresent white, middle-class, English-speaking families. JDRF has recognized this gap and is actively working to recruit advocates from minority and low-income communities through partnerships with organizations like the American Diabetes Association and Beyond Type 1. The organization now provides translation services and financial support for participant engagement to ensure a more representative voice in shaping research.

Finally, there is the risk that patient input might inadvertently steer research away from foundational science that yields long-term benefits. For example, a survey might rank beta cell regeneration lower than immediate glucose control because patients are less familiar with its potential. JDRF balances this by separating the scientific review process from the patient advisory process: patients prioritize areas based on lived experience, but scientists decide the best approaches within each area. This division ensures that high-risk fundamental research on immune tolerance or beta cell biology continues to receive funding, even if it is not the most popular topic in a survey.

Future Directions: Expanding the Patient-Centered Model

JDRF continues to refine its patient engagement strategies. The organization is piloting a “patient research partner” program, where individuals with T1D are embedded directly into academic labs for short-term rotations. These partners provide real-time feedback on experiments and help researchers understand the clinical relevance of their work. Early results from pilot studies show that labs with patient partners have higher rates of translating findings into clinical trials.

JDRF is also leveraging digital tools to scale engagement. The JDRF Research Map is an online platform where patients can browse funded projects, leave comments, and see how research progresses. This transparency builds trust and allows patients to feel ownership of the research enterprise. Additionally, the organization is exploring the use of wearable device data donated by volunteers to create real-world evidence that complements traditional clinical trials. Patients who contribute their data are directly involved in shaping the research questions those data can answer.

Another frontier is pediatric research. Children with T1D cannot always articulate their needs in the same way adults can, so JDRF has developed age-appropriate consultation methods, including art-based activities and play-based focus groups. This ensures that the voices of the youngest patients—who are the primary beneficiaries of prevention and cure research—are not overlooked.

Conclusion

JDRF’s patient-centered approach is more than a philosophy; it is a systematic, evidence-based strategy that has demonstrably altered the course of T1D research. By insisting that the person with diabetes—not just the scientist—drives priorities, JDRF has accelerated the development of life-changing technologies like CGMs and artificial pancreas systems, while simultaneously elevating the importance of psychosocial well-being and health equity. The model does not dismiss the need for rigorous science; it ensures that science serves the people it is meant to help.

As the organization looks ahead to the goal of preventing, curing, and managing T1D more effectively, its commitment to patient engagement will remain central. The challenges are significant—funding competition, scientific uncertainty, and the need for inclusive representation—but the track record shows that when patients are at the table, research becomes more relevant, more efficient, and more impactful. JDRF has proven that the most powerful direction for diabetes research comes not from a laboratory brainstorm alone, but from the lived experience of millions who navigate the disease every day. That lesson is one that the entire medical research community would do well to learn.

For more information on how JDRF sets its research priorities, visit the official JDRF Research page. To learn about the clinical trials influenced by patient input, see the ClinicalTrials.gov database. Additional insights on patient-centered research in diabetes can be found through the Diabetes Research Institute and the National Institute of Diabetes and Digestive and Kidney Diseases. For community-driven advocacy efforts, explore Beyond Type 1.